Your browser doesn't support javascript.
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.
Valdes-Balbin, Yury; Santana-Mederos, Darielys; Quintero, Lauren; Fernández, Sonsire; Rodriguez, Laura; Sanchez Ramirez, Belinda; Perez-Nicado, Rocmira; Acosta, Claudia; Méndez, Yanira; Ricardo, Manuel G; Hernandez, Tays; Bergado, Gretchen; Pi, Franciscary; Valdes, Annet; Carmenate, Tania; Ramirez, Ubel; Oliva, Reinaldo; Soubal, Jean-Pierre; Garrido, Raine; Cardoso, Felix; Landys, Mario; Gonzalez, Humberto; Farinas, Mildrey; Enriquez, Juliet; Noa, Enrique; Suarez, Anamary; Fang, Cheng; Espinosa, Luis A; Ramos, Yassel; González, Luis Javier; Climent, Yanet; Rojas, Gertrudis; Relova-Hernández, Ernesto; Cabrera Infante, Yanelys; Losada, Sum Lai; Boggiano, Tammy; Ojito, Eduardo; León, Kalet; Chiodo, Fabrizio; Paquet, Françoise; Chen, Guang-Wu; Rivera, Daniel G; Garcia-Rivera, Dagmar; Verez Bencomo, Vicente.
  • Valdes-Balbin Y; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Santana-Mederos D; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Quintero L; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Fernández S; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Rodriguez L; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Sanchez Ramirez B; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Perez-Nicado R; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Acosta C; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Méndez Y; Laboratory of Synthetic and Biomolecular Chemistry, Faculty of Chemistry, University of Havana, Zapata y G, Havana 10400, Cuba.
  • Ricardo MG; Laboratory of Synthetic and Biomolecular Chemistry, Faculty of Chemistry, University of Havana, Zapata y G, Havana 10400, Cuba.
  • Hernandez T; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Bergado G; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Pi F; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Valdes A; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Carmenate T; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Ramirez U; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Oliva R; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Soubal JP; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Garrido R; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Cardoso F; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Landys M; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Gonzalez H; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Farinas M; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Enriquez J; National Civil Defense Research Laboratory, Mayabeque 32700, Cuba.
  • Noa E; National Civil Defense Research Laboratory, Mayabeque 32700, Cuba.
  • Suarez A; National Civil Defense Research Laboratory, Mayabeque 32700, Cuba.
  • Fang C; Shanghai Fenglin Glycodrug Promotion Center, Shanghai 200032, China.
  • Espinosa LA; Center for Genetic Engineering and Biotechnology, Ave 31 e/158 y 190, Havana 10600, Cuba.
  • Ramos Y; Center for Genetic Engineering and Biotechnology, Ave 31 e/158 y 190, Havana 10600, Cuba.
  • González LJ; Center for Genetic Engineering and Biotechnology, Ave 31 e/158 y 190, Havana 10600, Cuba.
  • Climent Y; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Rojas G; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Relova-Hernández E; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Cabrera Infante Y; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Losada SL; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Boggiano T; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Ojito E; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • León K; Center of Molecular Immunology, P.O. Box 16040, 216 St., Havana, Cuba.
  • Chiodo F; Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.
  • Paquet F; Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081HV, The Netherlands.
  • Chen GW; Institute of Biomolecular Chemistry, National Research Council (CNR), Pozzuoli 80078, Napoli, Italy.
  • Rivera DG; Centre de Biophysique Moléculaire, CNRS UPR 4301, rue Charles Sadron F-45071, Orléans, Cedex 2, France.
  • Garcia-Rivera D; Chengdu Olisynn Biotech. Co. Ltd., and State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China.
  • Verez Bencomo V; Laboratory of Synthetic and Biomolecular Chemistry, Faculty of Chemistry, University of Havana, Zapata y G, Havana 10400, Cuba.
ACS Chem Biol ; 16(7): 1223-1233, 2021 07 16.
Article in English | MEDLINE | ID: covidwho-1294432
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines at an unprecedented pace. Vaccines approved for use and those in development intend to elicit neutralizing antibodies to block viral sites binding to the host's cellular receptors. Virus infection is mediated by the spike glycoprotein trimer on the virion surface via its receptor binding domain (RBD). Antibody response to this domain is an important outcome of immunization and correlates well with viral neutralization. Here, we show that macromolecular constructs with recombinant RBD conjugated to tetanus toxoid (TT) induce a potent immune response in laboratory animals. Some advantages of immunization with RBD-TT conjugates include a predominant IgG immune response due to affinity maturation and long-term specific B-memory cells. These result demonstrate the potential of the conjugate COVID-19 vaccine candidates and enable their advance to clinical evaluation under the name SOBERANA02, paving the way for other antiviral conjugate vaccines.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tetanus Toxoid / Vaccines, Conjugate / Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibody Formation Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: ACS Chem Biol Year: 2021 Document Type: Article Affiliation country: Acschembio.1c00272

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tetanus Toxoid / Vaccines, Conjugate / Antibodies, Neutralizing / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibody Formation Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Animals Language: English Journal: ACS Chem Biol Year: 2021 Document Type: Article Affiliation country: Acschembio.1c00272